Windtree Therapeutics, Inc.

1.22 USD
+0.31 (+34.79%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Windtree Therapeutics, Inc. stock is up 15.09% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 28 December’s closed higher than November.

About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trials for heart failure, and AEROSURF, an aerosolized KL4 surfactant.